FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

GLENMARK Share Price Discussion

Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Sector: Pharmaceuticals and health care

GLENMARK Rating

3.2/5 (13 Ratings)
GLENMARK Share Price *
211.75 +5.9 (2.87%)
* (quote may be delayed)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

You can also check GLENMARK share price target recommended by brokerages.

GLENMARK Discussion Forum

@Tulasi9 • Reputation: 358
GLENMARK APR20 FUT

Type
Buy
Instrument
GLENMARK APR20 FUT
Entry Price
₹203
Price@Trade
₹203.65
Target Price
₹207
Stop Price
₹200.5
Valid Till
Mar 31, 2020 3:20 AM
Margin
₹105,282.94 approx for 1400 Qty
Status
Exited
Exit Price
₹203.5
Net P&L
0.66% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 5:36 AM

Update
Trade Entered
Entry Price
₹203
Tulasi @Tulasi9
Yesterday 6:17 AM

Update
Exited
Exit Price
₹203.5
Net P&L
0.66% Profit
@Tulasi9 • Reputation: 358
GLENMARK APR20 FUT

Type
Buy
Instrument
GLENMARK APR20 FUT
Entry Price
₹203
Price@Trade
₹203.65
Target Price
₹207
Stop Price
₹200.5
Valid Till
Mar 31, 2020 3:20 AM
Margin
₹105,282.94 approx for 1400 Qty
Status
Exited
Exit Price
₹204
Net P&L
1.33% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Yesterday 5:36 AM

Update
Trade Entered
Entry Price
₹203
Tulasi @Tulasi9
Yesterday 6:25 AM

Update
Exited
Exit Price
₹204
Net P&L
1.33% Profit
@marketbull • Reputation: -30,317
GLENMARK APR20 FUT

Type
Buy
Instrument
GLENMARK APR20 FUT
Entry Price
₹202.15
Price@Trade
₹202.15
Target Price
₹300
Stop Price
₹190
Valid Till
Mar 31, 2020 3:20 AM
Margin
₹104,918.81 approx for 1400 Qty
Status
Exited
Exit Price
₹206.2
Net P&L
5.4% Profit
Like
reply
Reply (1)
Latest replies
BULL KING @marketbull
Yesterday 7:38 AM

Update
Exited
Exit Price
₹206.2
Net P&L
5.4% Profit
@JetageMatrixSystems • Reputation: 176,564
GLENMARK APR20 FUT

Type
Buy
Instrument
GLENMARK APR20 FUT
Entry Price
₹196.65
Price@Trade
₹197.6
Target Price
₹255
Stop Price
₹161  ₹202.65
Valid Till
Apr 30, 2020 3:20 AM
Margin
₹104,533.37 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹202.65
Net P&L
8.04% Profit
testing futures vs option trading @ price discovered
Like
reply
Reply (3)
Latest replies
TrackerBot @trackerbot
Mar 30 7:43 AM

Update
Trade Entered
Entry Price
₹196.65
J2K @JetageMatrixSystems
Yesterday 2:54 AM

Update
Stoploss Trailed
Price @ Update
₹203.4
Original SL
₹161
New SL
₹202.65
TrackerBot @trackerbot
Yesterday 2:59 AM

Update
Stoploss Hit
Exit Price
₹202.65

GLENMARK - chart - 687995
Glenmark abv 217 tgt 220, 224, 227, 230, 224sl 212
Like
reply
Reply
@mohan-B1lZEEB1E • Reputation: -29,958
GLENMARK MAR20 220 CE

Type
Buy
Instrument
GLENMARK MAR20 220 CE
Entry Price
₹0.6
Price@Trade
₹0.6
Target Price
₹1.2
Stop Price
₹0
Valid Till
Mar 26, 2020 3:20 AM
Margin
₹840 approx for 1400 Qty
Status
Exited
Exit Price
₹0.5
Net P&L
-16.67% Loss
Like
reply
Reply (1)
Latest replies
mohan @mohan-B1lZEEB1E
Mar 26 5:02 AM

Update
Exited
Exit Price
₹0.5
Net P&L
-16.67% Loss
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹193.1
Price@Trade
₹193.1
Target Price
₹430
Stop Price
₹80
Valid Till
Mar 25, 2021 3:20 AM
Margin
₹193.1 approx for 1 Qty
Status
Exited
Exit Price
₹202.7
Net P&L
4.97% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹202.7
Net P&L
4.97% Profit
@newsbot • Reputation: 2,570
Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets
"Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Dapagliflozin tablets, 5 mg and 10 mg," Glenmark said in a filing to BSE.
Moneycontrol
Like
reply
Reply
@sheik325 • Reputation: -2,620
GLENMARK MAR20 200 PE

Type
Buy
Instrument
GLENMARK MAR20 200 PE
Entry Price
₹16.2
Price@Trade
₹16.2
Target Price
₹20
Stop Price
₹13
Valid Till
Mar 18, 2020 3:20 AM
Margin
₹22,680 approx for 1400 Qty
Status
Target Achieved
Exit Price
₹20
Net P&L
23.46% Profit
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Mar 18 7:44 AM

Update
Target Achieved
Exit Price
₹20
@tradingfab • Reputation: 895

16-03-20 Intraday BUY GLENMARK in cash
only Above @ 240
SL 234.50
TGT 243-245, 248, 251
Like
reply
Reply (1)
Latest replies
Sameer  @tradingfab
Mar 16 4:27 AM

Hit 245 🔥🔥🚀🚀🚀
@Santhoshstreet • Reputation: -4,037
Santhoshtreet in GLENMARK
Buy Glenmark

Rocket
Like
reply
Reply
@tradehunk • Reputation: -1,969
GLENMARK MAR20 FUT

Type
Sell
Instrument
GLENMARK MAR20 FUT
Entry Price
₹234
Price@Trade
₹234
Target Price
₹220
Stop Price
₹247
Valid Till
Mar 17, 2020 3:20 AM
Margin
₹126,967.22 approx for 1400 Qty
Status
Exited
Exit Price
₹224.15
Net P&L
10.86% Profit
Like
reply
Reply (1)
Latest replies
Trade Hunk @tradehunk
Mar 16 5:53 AM

Update
Exited
Exit Price
₹224.15
Net P&L
10.86% Profit
@Santhoshstreet • Reputation: -4,037

Buy Glenmark
Like
reply
Reply
@databot • Reputation: 4,481

Nirmal Bang target on GLENMARK
Date: 04-Mar-20 Broker: Nirmal Bang Price @ Call: 287.38 Target: 390 Recommendation: BUY
Like
reply
Reply
@guptan • Reputation: 2,978

GLENMARK - chart - 660507
GLENMARK
Like
reply
Reply
GLENMARK APR20 FUT

Type
Buy
Instrument
GLENMARK APR20 FUT
Entry Price
₹181
Price@Trade
₹181
Target Price
₹310
Stop Price
₹120
Valid Till
Apr 13, 2020 3:20 AM
Margin
₹118,841.38 approx for 1400 Qty
Status
Exited
Exit Price
₹200
Net P&L
22.38% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹200
Net P&L
22.38% Profit
@niftystudy • Reputation: 131,593
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹201.3
Price@Trade
₹201.65
Target Price
₹400
Stop Price
₹160
Valid Till
Mar 12, 2021 3:20 AM
Margin
₹201.3 approx for 1 Qty
Status
Exited
Exit Price
₹214.5
Net P&L
6.56% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Mar 12 8:21 AM

Update
Trade Entered
Entry Price
₹201.3
NIFTYSTUDY @niftystudy
Mar 27 3:25 AM

Update
Exited
Exit Price
₹214.5
Net P&L
6.56% Profit
GLENMARK MAR20 FUT

Type
Buy
Instrument
GLENMARK MAR20 FUT
Entry Price
₹212
Price@Trade
₹212
Target Price
₹255
Stop Price
₹197
Valid Till
Mar 26, 2020 3:20 AM
Margin
₹78,327.76 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹197
Net P&L
-26.81% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Mar 12 8:31 AM

Update
Stoploss Hit
Exit Price
₹197
@ripulgupta • Reputation: 1,979
GLENMARK MAR20 FUT

Type
Sell
Instrument
GLENMARK MAR20 FUT
Entry Price
₹209.5
Price@Trade
₹209.5
Target Price
₹190
Stop Price
₹215
Valid Till
Mar 12, 2020 3:20 AM
Margin
₹77,856.31 approx for 1400 Qty
Status
Exited
Exit Price
₹200.3
Net P&L
16.54% Profit
Like
reply
Reply (1)
Latest replies
POCKET FULL @ripulgupta
Mar 12 6:53 AM

Update
Exited
Exit Price
₹200.3
Net P&L
16.54% Profit
@newsbot • Reputation: 2,570
Brokerages initiate 'buy' on 9 stocks in March, see 24-56% upside in a year
Correction is expected to continue, but this is the right time to accumulate quality stocks, most of experts feel
Moneycontrol
Like
reply
Reply
@ripulgupta • Reputation: 1,979
GLENMARK MAR20 FUT

Type
Sell
Instrument
GLENMARK MAR20 FUT
Entry Price
₹263
Price@Trade
₹263
Target Price
₹255
Stop Price
₹270
Valid Till
Mar 11, 2020 3:20 AM
Margin
₹85,516.05 approx for 1400 Qty
Status
Exited
Exit Price
₹260.85
Net P&L
3.52% Profit
Like
reply
Reply (1)
Latest replies
POCKET FULL @ripulgupta
Mar 11 2:47 AM

Update
Exited
Exit Price
₹260.85
Net P&L
3.52% Profit

Forwarded
Glenmark: Best Buy: Pharma Sales rise 12% in Feb
40% Upside Target: Glenmark
CLSA on Glenmark
Post 3Q results, *raise TP to Rs 420*
Believe vals are attractive considering strong India positioning, improving margin profile & likely decline in leverage
Favourable data of...
Read more...
Like
reply
Reply
@newsbot • Reputation: 2,570
Pharma sales see rebound in February on back of respiratory drugs
Eight of the top 10 therapies registered a growth of more than 10 percent.
Moneycontrol
Like
reply
Reply
MILLIONAIREE CAPITAL in GLENMARK
GLENMARK MAR20 FUT
Trade entered: Buy GLENMARK MAR20 FUT @275.75 T...

Till now 292.55+++😊😊😊
Like
reply
Reply
MILLIONAIREE CAPITAL in GLENMARK
GLENMARK MAR20 FUT
Trade entered: Buy GLENMARK MAR20 FUT @275.75 T...

Mark my words this stock is going to rock higher....
Like
reply
Reply
GLENMARK MAR20 FUT

Type
Buy
Instrument
GLENMARK MAR20 FUT
Entry Price
₹275.75
Price@Trade
₹275.75
Target Price
₹309
Stop Price
₹265
Valid Till
Mar 11, 2020 3:20 AM
Margin
₹85,575.74 approx for 1400 Qty
Status
Exited
Exit Price
₹291.3
Net P&L
25.44% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹291.3
Net P&L
25.44% Profit
@balasubramaniam • Reputation: -109,990
GLENMARK MAR20 250 PE

Type
Buy
Instrument
GLENMARK MAR20 250 PE
Entry Price
₹5.05
Price@Trade
₹5.05
Target Price
₹11
Stop Price
₹2
Valid Till
Mar 26, 2020 3:20 AM
Margin
₹7,070 approx for 1400 Qty
Status
Exited
Exit Price
₹5.6
Net P&L
10.89% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹5.6
Net P&L
10.89% Profit
@newsbot • Reputation: 2,570
Glenmark inks licensing pact with Hikma for commercialisation of nasal spray Ryaltris in US
The licensing pact for Ryaltris has been signed between the company's Swiss subsidiary, Glenmark Specialty SA and Hikma Pharmaceuticals PLC (Hikma).
Moneycontrol
Like
reply
Reply
@100billionclub • Reputation: 2,107

STBT SELL GLENMARK FEB BELOW 293.80
Like
reply
Reply
@sriharinune • Reputation: 28,180
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹300
Price@Trade
₹306.1
Target Price
₹295
Stop Price
₹302
Valid Till
Feb 25, 2020 3:20 AM
Margin
₹300 approx for 1 Qty
Status
Target Achieved
Exit Price
₹295
Net P&L
1.67% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 25 3:11 AM

Update
Trade Entered
Entry Price
₹300
TrackerBot @trackerbot
Feb 25 3:20 AM

Update
Target Achieved
Exit Price
₹295
GLENMARK MAR20 FUT

Type
Sell
Instrument
GLENMARK MAR20 FUT
Entry Price
₹297
Price@Trade
₹306.5
Target Price
₹280
Stop Price
₹302
Valid Till
Mar 3, 2020 3:20 AM
Margin
₹93,106.11 approx for 1400 Qty
Status
Exited
Exit Price
₹295.5
Net P&L
2.26% Profit
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 25 3:12 AM

Update
Trade Entered
Entry Price
₹297

Update
Exited
Exit Price
₹295.5
Net P&L
2.26% Profit
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹310
Price@Trade
₹308.6
Target Price
₹301
Stop Price
₹314.5
Valid Till
Feb 24, 2020 3:20 AM
Status
Expired before entry
Sell GLENMARK in cash@ 310 SL 314.50 TGT 301.00
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 24 8:50 AM

Update
Expired before entry
Price @ Update
₹300.4
GLENMARK FEB20 FUT

Type
Sell
Instrument
GLENMARK FEB20 FUT
Entry Price
₹311
Price@Trade
₹310.85
Target Price
₹301
Stop Price
₹315
Valid Till
Feb 24, 2020 3:20 AM
Status
Exited before entry
SELL GLENMARK CASH&FUTUR BOTH
Like
reply
Reply (1)
Latest replies

Update
Exited before entry
Price @ Update
₹309
@sifm • Reputation: 10,611
GLENMARK FEB20 FUT

Type
Buy
Instrument
GLENMARK FEB20 FUT
Entry Price
₹327
Price@Trade
₹326.55
Target Price
₹331
Stop Price
₹323
Valid Till
Feb 20, 2020 3:20 AM
Status
Exited before entry
Like
reply
Reply (1)
Latest replies
Ashish Tiwari @sifm
Feb 20 8:45 AM

Update
Exited before entry
Price @ Update
₹322.5
@sid-H16FVBj4V • Reputation: 628
GLENMARK FEB20 FUT

Type
Buy
Instrument
GLENMARK FEB20 FUT
Entry Price
₹326.3
Price@Trade
₹326.85
Target Price
₹327.3
Stop Price
₹325.8
Valid Till
Feb 20, 2020 3:20 AM
Margin
₹92,968.23 approx for 1400 Qty
Status
Stoploss Hit
Exit Price
₹325.8
Net P&L
-0.75% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 20 6:03 AM

Update
Trade Entered
Entry Price
₹326.3
TrackerBot @trackerbot
Feb 20 6:06 AM

Update
Stoploss Hit
Exit Price
₹325.8
@balaji3516 • Reputation: 13,578
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹322.5
Price@Trade
₹322.05
Target Price
₹31
Stop Price
₹324.2
Valid Till
Feb 20, 2020 3:20 AM
Margin
₹322.5 approx for 1 Qty
Status
Exited
Exit Price
₹323.4
Net P&L
-0.28% Loss
Like
reply
Reply (2)
Latest replies
TrackerBot @trackerbot
Feb 20 4:19 AM

Update
Trade Entered
Entry Price
₹322.5
Balaji  @balaji3516
Feb 20 5:38 AM

Update
Exited
Exit Price
₹323.4
Net P&L
-0.28% Loss
@nikuj • Reputation: 0
Q. What is the view on Glenmark
Like
reply
Reply (2)
Latest replies

May Test 300-295 & Reverse 👍
Balaji  @balaji3516
Feb 17 2:18 AM

Having support at 295-297 levels ..if it holds then upmove..but it is risky to enter now
@mrk-BkWUfpPbL • Reputation: 0

Is it going to fall or rise?
Like
reply
Reply
GLENMARK

Type
Sell
Instrument
GLENMARK
Entry Price
₹315.9
Price@Trade
₹315.9
Target Price
₹310
Stop Price
₹319
Valid Till
Feb 17, 2020 3:20 AM
Margin
₹315.9 approx for 1 Qty
Status
Exited
Exit Price
₹312.4
Net P&L
1.11% Profit
Like
reply
Reply (1)
Latest replies

Update
Exited
Exit Price
₹312.4
Net P&L
1.11% Profit
@Zerodhapartner • Reputation: 351

GLENMARK - chart - 604725

Like
reply
Reply
Alok Bihani in GLENMARK
Amid the coronavirus Pharma industry is making ...

GLENMARK - chart - 604694
BANG BANG BANG !!! hits all target on long side.
Sorry for delay in update. Chart attached for refernce.
will post new levels ASAP. Dm me for further details if required.
Like
reply
Reply (2)
Latest replies
lost somewhere @lost
Feb 15 8:39 AM

Tell something about coal india stuck in there

Will post my view with charts nd levels on Coal India tonight..pls chck Coal India forum
@newsbot • Reputation: 2,570
Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn
The company had posted a net profit of Rs 116.34 crore in the corresponding period of the previous financial year, Glenmark Pharmaceuticals said in a filing to the BSE.
Moneycontrol
Like
reply
Reply
@newsbot • Reputation: 2,570
Taking Stock | Supreme Court raps telcos for not paying up; Sensex falls below 50-DMA
The apex court's stance weighed on financial stocks also because of their exposure to the sector.
Moneycontrol
Like
reply
Reply

Reversal day for GLENMARK is Feb 17 based on Gann Astro method
Like
reply
Reply (2)
Latest replies

GLENMARK - 606929
GLENMARK reversal day results
300 to 346 and to 310 - 7 % down on our reversal day
@balrambull • Reputation: -1
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹329.45
Price@Trade
₹329.45
Target Price
₹340
Stop Price
₹326
Valid Till
Feb 12, 2020 3:20 AM
Margin
₹329.45 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹326
Net P&L
-1.05% Loss
Like
reply
Reply (1)
Latest replies
TrackerBot @trackerbot
Feb 12 5:53 AM

Update
Stoploss Hit
Exit Price
₹326
@newsbot • Reputation: 2,570
Glenmark board to consider fund raising options on February 14
The Mumbai-based firm plans to raise funds either through issuance of bonds or debentures, non-convertible debt instruments or any other securities or any combination thereof, of any of the above, it added.
Moneycontrol
Like
reply
Reply
@rajivkumarjha • Reputation: -190,208
GLENMARK FEB20 330 CE

Type
Buy
Instrument
GLENMARK FEB20 330 CE
Entry Price
₹11.4
Price@Trade
₹11.4
Target Price
₹20
Stop Price
₹9.5
Valid Till
Feb 17, 2020 3:20 AM
Margin
₹15,960 approx for 1400 Qty
Status
Exited
Exit Price
₹13.5
Net P&L
18.42% Profit
Like
reply
Reply (1)
Latest replies
robotrade @rajivkumarjha
Feb 11 3:24 AM

Update
Exited
Exit Price
₹13.5
Net P&L
18.42% Profit
@tradingwiz • Reputation: 672
tradingwiz in GLENMARK

Wonderfully Hit all Targets... Enjoy friends
Like
reply
Reply
@nishantshah91 • Reputation: 1,632
GLENMARK

Type
Buy
Instrument
GLENMARK
Entry Price
₹324.5
Price@Trade
₹324.7
Target Price
₹350
Stop Price
₹312.9
Valid Till
Mar 6, 2020 3:20 AM
Margin
₹324.5 approx for 1 Qty
Status
Stoploss Hit
Exit Price
₹312.9
Net P&L
-3.57% Loss
T1 350 T2 360
Like
reply
Reply (5)
Latest replies
TrackerBot @trackerbot
Feb 7 3:25 AM

Update
Trade Entered
Entry Price
₹324.5
TradeAdda @nishantshah91
Feb 7 4:29 AM

326.50 from 324.50
TradeAdda @nishantshah91
Feb 7 4:38 AM

329.25 up almost 1.50% Intraday. Lot Size 1400.
TradeAdda @nishantshah91
Feb 11 9:09 AM

Made high 334.75 today from entry 324.50 lot size 1400 can keep Booking part as per comfort. #TradeAdda
TrackerBot @trackerbot
Feb 17 3:35 AM

Update
Stoploss Hit
Exit Price
₹312.9
@tradingwiz • Reputation: 672

GLENMARK - chart - 586980

Like
reply
Reply
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK Share Price - Technicals

    keyboard_arrow_down
    GLENMARK - 52 Week High₹659.3
    GLENMARK - 52 Week Low₹161.65
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    4-Mar-20Nirmal BangBuy390
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    25-Nov-19Geojit Financial ServicesHold366
    3-Sep-19Geojit Financial ServicesSell338
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Mar 31199208197205.85
    Mar 30197199.55190195.75
    Mar 27210.75216.2197.05199.15
    Mar 26195216.35192208.2
    Mar 25190196.8187.35191.55
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹224.7
    30 Day Moving Average₹253.33
    50 Day Moving Average₹285.82
    100 Day Moving Average₹310.76
    200 Day Moving Average₹352.63
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Mar 23 7:23 AM
    Glenmark gets tentative nod from USFDA for generic type-2 diabetes tablets
    Moneycontrol
    NewsBot
    Mar 11 8:08 AM
    Brokerages initiate 'buy' on 9 stocks in March, see 24-56% upside in a year
    Moneycontrol
    NewsBot
    Mar 9 2:23 AM
    Pharma sales see rebound in February on back of respiratory drugs
    Moneycontrol
    NewsBot
    Feb 27 8:33 AM
    Glenmark inks licensing pact with Hikma for commercialisation of nasal spray Ryaltris in US
    Moneycontrol
    NewsBot
    Feb 14 2:58 AM
    Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn
    Moneycontrol
    NewsBot
    Feb 14 10:43 AM
    Taking Stock | Supreme Court raps telcos for not paying up; Sensex falls below 50-DMA
    Moneycontrol
    NewsBot
    Feb 11 1:08 AM
    Glenmark board to consider fund raising options on February 14
    Moneycontrol
    NewsBot
    Jan 31 4:53 AM
    Low rollover seen ahead of Budget; Nifty rollovers at 66.30% for Feb series
    Moneycontrol
    NewsBot
    Oct 23 5:13 AM
    SBI Life, ICICI Pru, Siemens in MSCI India Index? Here's what Morgan Stanley thinks
    Moneycontrol
    NewsBot
    Oct 17 4:53 AM
    Glenmark Pharma gets USFDA nod for prostate cancer treatment drug
    Moneycontrol
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Dr. Reddy's Laboratories Ltd. Sector...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Piramal Enterprises Ltd. Sector: Phar...
    Divi's Laboratories Ltd. Sector: Pha...
    Strides Pharma Science Ltd. Sector: P...
    Apollo Hospitals Enterprise Ltd. Sec...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.